Topics

Aimmune faces crucial FDA panel vote on first peanut allergy drug

12:40 EDT 12 Sep 2019 | BioPharmaDive

The allergy-focused biotech faces a critical test Friday. Here's what to expect from the FDA advisory committee's review.

Original Article: Aimmune faces crucial FDA panel vote on first peanut allergy drug

NEXT ARTICLE

More From BioPortfolio on "Aimmune faces crucial FDA panel vote on first peanut allergy drug"

Quick Search

Relevant Topics

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...